Drug Discovery and Development
GE Healthcare addresses the growing challenges of providing safer, efficacious and cost-effective therapies. Our products cover several approaches to producing therapeutics, from small molecule-based drug discovery and biotherapeutics discovery, to development and bioprocessing. Our drug discovery products enable deeper insights into drug compound action to better predict success in development. We also provide bioreactors, chromatography, and filtration products for bioprocess applications, as well as advanced systems for high content cell imaging and label-free protein interaction analysis.
The development of new therapeutics lies at the core of the efforts to improve human healthcare. Finding new therapeutic molecular targets and developing safe, efficacious drugs at a reasonable cost is still an enormous challenge. Major initiatives in genomics and proteomics are now providing many new potential drug targets. Traditional pharmaceutical development, based on small organic compounds, is being increasingly complemented with developments in protein-based biotherapeutics, nucleic acid technologies such as anti-sense oligonucleotides, RNA interference (RNAi), and the rapidly emerging field of cell-based therapies. New approaches such as translational medicine (predictive science) and interactomics are being adopted, with priority increasingly shifting toward understanding biological mechanisms to better predict success.
Newer and ever more reliable technologies are enabling the production of biotherapeutics and even whole cells to augment or replace small organic compounds
Deeper insights into mechanisms of action of potential drug compounds significantly aid in the selection and optimization of a single Investigational New Drug from hundreds of thousands of compounds
It is essential to identify drug targets, understand their role in disease processes, and to establish their functional partners